Motif Bio (MTFB) Priced

Late-stage biotech developing antibiotics for multi-drug resistant bacteria.

Health Care - Biotechnology

IPO Performance
Latest Trade $6.38 0.00 (0.0%)
First Day Return -19.9%
Return from IPO -8.5%
 
Motif Bio IPO News more
  • .
IPO Data
IPO File Date 07/13/2016
Offer Price $6.98
Price Range $8.38 - $8.38
Offer Shares (mm) 3.6
Deal Size ($mm) 25
 
IPO Data
IPO Date 11/18/2016
Offer Price $6.98
Price Range $8.38 - $8.38
Offer Shares (mm) 3.6
Deal Size ($mm) $25
 
Underwriters
more
Business Overview
We are a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. The discovery of new antibiotics has not kept pace with the increasing incidence of resistant, difficult-to-treat bacteria. One of the biggest threats of antibiotic resistance is from MRSA (methicillin resistant Staphylococcus aureus), a leading cause of hospital-acquired infections and a growing cause of infections in healthy people in the general community. In 2013, the Centers of Disease Control reported that at least two million people became infected with antibiotic-resistant bacteria and at least 23,000 Americans died as a direct result of these infections. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia, including ventilator associated bacterial pneumonia, infections which are often caused by MRSA. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous, or IV, formulation of iclaprim, for the treatment of ABSSSI.
We are a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. The discovery of new antibiotics has not kept pace with the increasing incidence...
more
Company Data
Headquarters New York, NY
Founded 2003
Employees 4
Website www.motifbio.com
 

Performance vs. IPO Index (IPOUSA)